丙酮酸脱氢酶复合体通过代谢调控减轻LPS诱导的内皮屏障功能障碍
本研究以人脐静脉内皮细胞(HUVECs)和C57BL/6小鼠为对象,用脂多糖(LPS)建立内毒素血症模型。LPS增加内皮细胞基础糖酵解、补偿性糖酵解和乳酸分泌,激活丙酮酸脱氢酶复合体(PDHC)的二氯乙酸(DCA)可逆转这些改变,使PDHC保持活性去磷酸化状态,防止乳酸产生和HUVECs单层屏障功能障碍。体内实验显示LPS处理小鼠乳酸水平和血管通透性增加,DCA预处理可减弱这些增加。LPS处理HUVEC模型中DCA逆转PDH E1α Ser293和Ser300磷酸化以恢复PDHC活性,LPS还增加PDH E1α乙酰化水平。研究提示激活PDHC可能是治疗LPS诱导内皮屏障功能障碍的治疗靶点。
要点
- 在LPS诱导的内毒素血症模型中,LPS增加内皮细胞基础糖酵解、补偿性糖酵解和乳酸分泌,提示糖酵解水平升高。
- DCA激活PDHC可逆转LPS诱导的糖酵解,使PDHC保持活性去磷酸化状态,防止乳酸产生和HUVECs单层屏障功能障碍。
- 体内实验显示LPS处理小鼠乳酸水平和血管通透性增加,DCA预处理可减弱这些增加。
- LPS处理HUVEC模型中,DCA逆转PDH E1α Ser293和Ser300磷酸化以恢复PDHC活性;LPS处理增加PDH E1α乙酰化水平。
- 作者认为激活PDHC可能代表治疗LPS诱导内皮屏障功能障碍的治疗靶点。
适用人群与场景
- 人脐静脉内皮细胞(HUVECs)和C57BL/6小鼠,以脂多糖(LPS)处理作为内毒素血症模型。
处置流程与药物剂量
- 使用二氯乙酸(DCA)激活PDHC:在HUVECs和LPS处理小鼠中预处理DCA,可逆转LPS诱导的糖酵解、减少乳酸产生并减轻内皮屏障功能障碍。
研究设计与关键结果
- LPS增加HUVECs基础糖酵解、补偿性糖酵解和乳酸分泌。
- DCA激活PDHC逆转LPS诱导的糖酵解,使PDHC保持活性去磷酸化状态,防止乳酸产生和HUVECs单层屏障功能障碍(经跨内皮电阻和FITC-葡聚糖评估)。
- LPS处理小鼠乳酸水平和血管通透性增加,DCA预处理减弱这些增加。
- LPS处理HUVEC模型中,DCA逆转PDH E1α Ser293和Ser300磷酸化以恢复PDHC活性;免疫共沉淀显示LPS处理增加PDH E1α乙酰化水平。
证据类型、等级与局限
- 证据类型:体外细胞实验和动物实验(C57BL/6小鼠内毒素血症模型)。
- 局限:原文未报告局限性
对床旁实践的改变
- 作者认为激活PDHC可能代表治疗LPS诱导内皮屏障功能障碍的治疗靶点。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Sepsis is a fatal health issue induced by an aberrant host response to infection, and it correlates with organ damage and a high mortality rate. Endothelial barrier dysfunction and subsequent capillary leakage play major roles in sepsis-induced multiorgan dysfunction. Anaerobic glycolysis is the primary metabolic mode in sepsis and the pyruvate dehydrogenase complex (PDHC) serves as a critical hub in energy regulation. Therefore, it is important to understand the role of PDHC in metabolic regulation during the development of sepsis-induced endothelial barrier dysfunction.In present study, human umbilical vein endothelial cells (HUVECs) and C57 BL/6 mice were treated with lipopolysaccharide (LPS) as models of endotoxemia. LPS increased basal glycolysis, compensatory glycolysis, and lactate secretion, indicating increased glycolysis level in endothelial cells (ECs). Activation of PDHC with dichloroacetate (DCA) reversed LPS-induced glycolysis, allowing PDHC to remain in the active dephosphorylated state, thereby preventing lactic acid production and HUVECs monolayers barrier dysfunction, as assessed by transendothelial electrical resistance and Fluorescein Isothiocyanate-labeled dextran. The in vivo study also showed that the lactate level and vascular permeability were increased in LPS-treated mice, but pretreatment with DCA attenuated these increases. The LPS-treated HUVEC model showed that DCA reversed LPS-induced phosphorylation of pyruvate dehydrogenase E1α Ser293 and Ser300 to restore PDHC activity. Immunoprecipitation results showed that LPS treatment increased the acetylation level of PDH E1α in HUVECs.Our study suggested that activation of PDHC may represent a therapeutic target for treatment of LPS-induced endothelial barrier dysfunction.
参考来源
- Mao L, Sun M, Chen Z, et al. The Pyruvate Dehydrogenase Complex Mitigates LPS-Induced Endothelial Barrier Dysfunction by Metabolic Regulation. Shock. 2022. PMID: 35759309. doi:10.1097/SHK.0000000000001931
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。